|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C1orf63 |
Gene summary for C1ORF63 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C1orf63 | Gene ID | 57035 |
| Gene name | arginine and serine rich protein 1 | |
| Gene Alias | C1orf63 | |
| Cytomap | 1p36.11 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | A0A024RAH6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57035 | C1orf63 | Pt13.a | Human | Liver | HCC | 4.58e-11 | 2.83e-01 | 0.021 |
| 57035 | C1orf63 | Pt13.b | Human | Liver | HCC | 2.01e-33 | 5.07e-01 | 0.0251 |
| 57035 | C1orf63 | Pt14.a | Human | Liver | HCC | 3.93e-13 | 4.87e-01 | 0.0169 |
| 57035 | C1orf63 | Pt14.b | Human | Liver | HCC | 4.39e-19 | 5.80e-01 | 0.018 |
| 57035 | C1orf63 | Pt14.d | Human | Liver | HCC | 1.41e-15 | 4.18e-01 | 0.0143 |
| 57035 | C1orf63 | GSM5353215_PA_AUG_PB_1B_S2 | Human | Prostate | Tumor | 2.91e-04 | 5.79e-01 | 0.1557 |
| 57035 | C1orf63 | GSM5353216_PA_PB1A_Pool_1_3_S50_L002 | Human | Prostate | Tumor | 1.72e-12 | 1.02e+00 | 0.159 |
| 57035 | C1orf63 | GSM5353217_PA_PB1A_Pool_2_S107_L004 | Human | Prostate | Tumor | 4.29e-06 | 8.71e-01 | 0.156 |
| 57035 | C1orf63 | GSM5353218_PA_PB1B_Pool_1_2_S74_L003 | Human | Prostate | Tumor | 6.49e-08 | 6.85e-01 | 0.1479 |
| 57035 | C1orf63 | GSM5353220_PA_PB1B_Pool_3_S51_L002 | Human | Prostate | Tumor | 9.10e-10 | 8.34e-01 | 0.1531 |
| 57035 | C1orf63 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 4.72e-31 | 9.19e-01 | 0.1633 |
| 57035 | C1orf63 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 2.44e-35 | 9.20e-01 | 0.1608 |
| 57035 | C1orf63 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 1.25e-30 | 1.00e+00 | 0.1604 |
| 57035 | C1orf63 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 3.38e-33 | 9.82e-01 | 0.1621 |
| 57035 | C1orf63 | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 9.14e-13 | 7.78e-01 | 0.1619 |
| 57035 | C1orf63 | GSM5353226_PA_PR5196-2_Pool_1_2_3_S54_L002 | Human | Prostate | Tumor | 4.97e-13 | 8.91e-01 | 0.159 |
| 57035 | C1orf63 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 1.23e-14 | 5.87e-01 | 0.1602 |
| 57035 | C1orf63 | GSM5353232_PA_PR5249_T1_S3_L001 | Human | Prostate | Tumor | 1.73e-03 | 6.74e-01 | 0.1439 |
| 57035 | C1orf63 | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 2.14e-14 | 7.89e-01 | 0.1608 |
| 57035 | C1orf63 | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 2.25e-14 | 9.22e-01 | 0.1622 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |